WO2021097227A1 - Thérapie cellulaire adoptive améliorée par des protéines de fusion à l'il-15 - Google Patents

Thérapie cellulaire adoptive améliorée par des protéines de fusion à l'il-15 Download PDF

Info

Publication number
WO2021097227A1
WO2021097227A1 PCT/US2020/060440 US2020060440W WO2021097227A1 WO 2021097227 A1 WO2021097227 A1 WO 2021097227A1 US 2020060440 W US2020060440 W US 2020060440W WO 2021097227 A1 WO2021097227 A1 WO 2021097227A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
complex
hspc
cancer
Prior art date
Application number
PCT/US2020/060440
Other languages
English (en)
Inventor
Peter Rhode
Original Assignee
Altor Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience, Llc filed Critical Altor Bioscience, Llc
Publication of WO2021097227A1 publication Critical patent/WO2021097227A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

L'invention concerne des polythérapies qui comprennent des cellules tueuses naturelles (NK), un super-agoniste d'IL-15 et/ou au moins un agent chimiothérapeutique, améliorant l'activité antitumorale des cellules NK. Dans certains modes de réalisation, une méthode de prévention ou de traitement du cancer comprend l'administration à un patient qui en a besoin d'une quantité efficace d'une thérapie cellulaire adoptive et d'une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'au moins un agent chimiothérapeutique, de manière à traiter le cancer.
PCT/US2020/060440 2019-11-14 2020-11-13 Thérapie cellulaire adoptive améliorée par des protéines de fusion à l'il-15 WO2021097227A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962935464P 2019-11-14 2019-11-14
US62/935,464 2019-11-14

Publications (1)

Publication Number Publication Date
WO2021097227A1 true WO2021097227A1 (fr) 2021-05-20

Family

ID=75912332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/060440 WO2021097227A1 (fr) 2019-11-14 2020-11-13 Thérapie cellulaire adoptive améliorée par des protéines de fusion à l'il-15

Country Status (1)

Country Link
WO (1) WO2021097227A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113599395A (zh) * 2021-09-22 2021-11-05 北京创世客生物技术有限公司 含有nk细胞的治疗癌症的药物组合物
CN115778951A (zh) * 2022-12-20 2023-03-14 南京邮电大学 阿莫西林在增强自然杀伤细胞的抗肿瘤活性中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170071965A1 (en) * 2003-02-19 2017-03-16 Case Western Reserve University Antimetabolite agent combinations in the treatment of cancer
US20170088597A1 (en) * 2015-09-25 2017-03-30 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
US20190046623A1 (en) * 2017-03-06 2019-02-14 Altor Bioscience Corporation Il-15-based fusions to il-12 and il-18

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170071965A1 (en) * 2003-02-19 2017-03-16 Case Western Reserve University Antimetabolite agent combinations in the treatment of cancer
US20170088597A1 (en) * 2015-09-25 2017-03-30 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
US20190046623A1 (en) * 2017-03-06 2019-02-14 Altor Bioscience Corporation Il-15-based fusions to il-12 and il-18

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOOGSTAD-VAN EVERT JANNEKE S, MAAS RALPH J, VAN DER MEER JOLIEN, CANY JEANNETTE, VAN DER STEEN SOPHIEKE, JANSEN JOOP H, MILLER JEF: "Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients", ONCOTARGET, vol. 9, 5 October 2018 (2018-10-05), pages 34810 - 34820, XP055823780 *
LUEVANO ET AL.: "Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy", CELLULAR & MOLECULAR IMMUNOLOGY, vol. 9, 18 June 2012 (2012-06-18), pages 310 - 320, XP055561634, DOI: 10.1038/cmi.2012.17 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113599395A (zh) * 2021-09-22 2021-11-05 北京创世客生物技术有限公司 含有nk细胞的治疗癌症的药物组合物
CN113599395B (zh) * 2021-09-22 2022-08-12 郑州源创吉因实业有限公司 含有nk细胞的治疗癌症的药物组合物
CN115778951A (zh) * 2022-12-20 2023-03-14 南京邮电大学 阿莫西林在增强自然杀伤细胞的抗肿瘤活性中的用途
CN115778951B (zh) * 2022-12-20 2024-04-09 南京邮电大学 阿莫西林在增强自然杀伤细胞的抗肿瘤活性中的用途

Similar Documents

Publication Publication Date Title
US20210228633A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
US20220133799A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
US11046782B2 (en) Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US11963980B2 (en) Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
US20200061116A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
EP3370742A1 (fr) Composition destinée à être utilisée en immunothérapie
US20200283728A1 (en) Modified t cells and uses thereof
WO2021097227A1 (fr) Thérapie cellulaire adoptive améliorée par des protéines de fusion à l'il-15
US20210008110A1 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
Meehan et al. Adoptive cellular therapy using cells enriched for NKG2D+ CD3+ CD8+ T cells after autologous transplantation for myeloma
AU2020350221A1 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
TW202038975A (zh) 多發性骨髓瘤之組合治療
KR20200035999A (ko) Nk-92 세포를 이용한 백혈병의 치료 및 억제
EP3787634A1 (fr) Immunothérapies à base d'inositol
US20230330186A1 (en) Treatment of immunosuppressed subjects
CN114729314A (zh) 用于癌症治疗的组合癌症疗法和细胞因子控制疗法
Kudo-Saito et al. Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
Cany et al. Decitabine enhances targeting of AML cells by CD34+ stem and progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice
WO2020105034A1 (fr) Cellules apoptotiques précoces destinées à être utilisées dans le traitement d'une sepsie
Langenkamp Immunorecognition of leukemic stem cells by NK cells: the role of HDAC inhibitors in NKG2D ligand-mediated anti-tumor responses in acute myeloid leukemia
Hatfield The anti-hypoxia-adenosinergic approach to the immunotherapy of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20888714

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19.08.2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20888714

Country of ref document: EP

Kind code of ref document: A1